+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Icosapent Ethyl Drugs Market - Global Forecast 2026-2032- Product Image
Icosapent Ethyl Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Icosapent Ethyl Drugs Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6123049
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Icosapent Ethyl Drugs Market is projected to reach USD 1.75 Billion in 2026. It is expected to continue growing at a CAGR of 6.66%, reaching USD 2.56 Billion by 2032.

Icosapent Ethyl Drugs: Executive Summary and Market Context

Icosapent ethyl is a purified eicosapentaenoic acid medicine used as an adjunct to diet and statin therapy for selected patients with elevated cardiovascular risk and, in some jurisdictions, severe hypertriglyceridemia. Its clinical positioning depends on approved indications, prescribing guidance, evidence interpretation, reimbursement, and access to lipid-management services. Because regulatory labels and clinical practice differ by jurisdiction, manufacturers, clinicians, and payers must evaluate each market independently.

Clinical Evidence and Regulatory Standards Are Reshaping Adoption

The category is being shaped by greater emphasis on cardiovascular-risk reduction rather than triglyceride lowering alone. Regulatory authorities and professional societies continue to distinguish between purified eicosapentaenoic acid and mixed omega-3 formulations, making formulation-specific evidence, adherence, safety monitoring, and appropriate patient selection central to use. Access is also influenced by prior authorization, generic substitution policies, pharmacovigilance requirements, and the integration of lipid management into broader prevention pathways.

Artificial Intelligence Strengthens Patient Identification and Evidence Generation

Artificial intelligence can support more consistent identification of patients with persistent hypertriglyceridemia or residual cardiovascular risk by analyzing longitudinal laboratory, medication, and clinical-record data. It can also improve adherence outreach, detect potential safety signals, optimize trial recruitment, and help clinicians interpret changing lipid profiles. These benefits require validated algorithms, representative data, transparent clinical oversight, privacy safeguards, and controls against inappropriate treatment recommendations or overreliance on automated risk scores.

Regional Insights: Access Depends on Regulation, Prevention Infrastructure, and Reimbursement

North America is characterized by established cardiovascular-prevention systems, comparatively broad lipid testing, and payer scrutiny of indication-specific use. Europe combines strong guideline-based care with country-level variation in reimbursement and health-technology assessment. Asia-Pacific presents diverse regulatory pathways, expanding chronic-disease services, and uneven access between metropolitan and rural populations. Latin America is influenced by public-private healthcare divides, affordability considerations, and the growing burden of cardiometabolic disease. The Middle East is strengthening specialized cardiovascular services while managing differences in procurement and coverage across countries. Africa faces constraints in diagnostic capacity, medicine affordability, and continuity of care, although targeted prevention programs can improve access.

Group Insights: Economic and Political Blocs Create Different Access Conditions

ASEAN markets differ substantially in regulatory maturity, reimbursement, and distribution infrastructure, making country-specific launch and evidence plans important. BRICS countries combine large and diverse patient populations with varied public procurement systems, domestic manufacturing capabilities, and access constraints. The European Union benefits from shared regulatory structures but retains national differences in pricing, reimbursement, and clinical implementation. G7 members generally have sophisticated cardiovascular-care systems and stringent evidence expectations, with continuing pressure on affordability. GCC countries often have concentrated healthcare procurement and advanced specialist services, while NATO members span different national systems and should not be treated as a single reimbursement market.

Country Insights: Local Labels and Health-System Priorities Matter

Australia and Canada require attention to national reimbursement processes and geographically uneven access. Brazil and Mexico must account for public-private system differences and affordability. China and India combine expanding chronic-disease care with substantial regional variation in diagnosis and treatment continuity. France, Germany, Italy, Spain, and the United Kingdom apply distinct assessment, pricing, and prescribing frameworks despite close clinical alignment. Japan emphasizes careful regulatory review and structured medical practice, while South Korea combines advanced hospitals with evolving coverage decisions. Russia presents additional considerations related to procurement, regulatory conditions, and healthcare-system access. In the United States, payer criteria, label interpretation, adherence, and cardiovascular-risk documentation are central implementation factors.

Actionable Priorities for Leaders in Icosapent Ethyl Drugs

Industry leaders should align every commercial and medical activity with jurisdiction-specific approved labeling and high-quality cardiovascular evidence. They should strengthen clinician education on patient selection, differentiate purified eicosapentaenoic acid from other omega-3 products, and build adherence programs that fit routine lipid-management workflows. Evidence strategies should include real-world outcomes, subgroup analyses, safety surveillance, and health-economic evaluations without overstating causal conclusions. Operationally, leaders should segment access plans by payer and care setting, establish reliable supply and pharmacovigilance processes, and deploy artificial intelligence only with clinical validation, governance, and human review.

Research Methodology: Evidence-Led, Jurisdiction-Specific Assessment

This executive summary uses the supplied market category as a therapeutic scope and synthesizes established considerations in cardiovascular prevention, lipid management, pharmaceutical regulation, reimbursement, and digital health. The assessment is organized across the required regions, economic and political groups, and countries, while avoiding unsupported market estimates or projections. Interpretation should be validated against current national labels, treatment guidelines, payer policies, safety communications, peer-reviewed clinical evidence, and local healthcare-access data before informing investment, launch, or treatment decisions.

Conclusion: Responsible Positioning Will Determine Clinical and Commercial Relevance

Icosapent ethyl drugs occupy a specialized role within cardiovascular-risk management, where clinical appropriateness and evidence quality are more important than broad omega-3 categorization. Regional and national differences in regulation, reimbursement, diagnostics, and continuity of care will determine practical access. Leaders that combine label-compliant medical strategy, patient-centered adherence support, robust safety oversight, and carefully governed data and artificial-intelligence capabilities will be better positioned to support appropriate use across diverse health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Icosapent Ethyl Drugs Market, by Product Type
7.1. Introduction
7.2. Pure Icosapent Ethyl Products
7.2.1. Ethyl Ester Capsules
7.2.2. Ethyl Ester Softgels
7.3. Combination Products
7.3.1. Icosapent Ethyl With Statins
7.3.2. Icosapent Ethyl With Other Lipid Modifiers
7.4. Research And Compounding Products
7.4.1. Clinical Trial Supplies
7.4.2. Compounded Preparations
8. Icosapent Ethyl Drugs Market, by Patient Age Group
8.1. Introduction
8.2. Adult
8.3. Geriatric
9. Icosapent Ethyl Drugs Market, by Indication
9.1. Introduction
9.2. Cardiovascular Risk Reduction
9.2.1. Atherosclerotic Cardiovascular Disease
9.2.2. Diabetes With Cardiovascular Risk Factors
9.3. Hypertriglyceridemia
9.3.1. Severe Hypertriglyceridemia
9.3.2. Mild To Moderate Hypertriglyceridemia
10. Icosapent Ethyl Drugs Market, by Application
10.1. Introduction
10.2. Cardiovascular Risk Reduction
10.3. Hypertriglyceridemia
11. Icosapent Ethyl Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Icosapent Ethyl Drugs Market, by End-User
12.1. Introduction
12.2. Clinic
12.3. Home Care
12.4. Hospital
13. Icosapent Ethyl Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Icosapent Ethyl Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Icosapent Ethyl Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Alembic Pharmaceuticals Ltd.
17.2. Amarin Corporation plc
17.3. Aurobindo Pharma Limited
17.4. Bayer AG
17.5. Biocon Limited
17.6. Cipla Limited
17.7. Dr. Reddy’s Laboratories Ltd.
17.8. GlaxoSmithKline plc
17.9. Glenmark Pharmaceuticals Ltd.
17.10. Himalaya Global Holdings Ltd.
17.11. Macleods Pharmaceuticals Ltd.
17.12. Merck & Co., Inc.
17.13. Mylan N.V.
17.14. Novartis AG
17.15. Novo Nordisk A/S
17.16. Pfizer Inc.
17.17. Sanofi S.A.
17.18. Sun Pharmaceutical Industries Ltd.
17.19. Takeda Pharmaceutical Company Limited
17.20. Torrent Pharmaceuticals Ltd.
17.21. Zydus Lifesciences Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Icosapent Ethyl Drugs Market, Years Considered for the Study
FIGURE 2. Global Icosapent Ethyl Drugs Market, Research Design
FIGURE 3. Global Icosapent Ethyl Drugs Market, Research Framework
FIGURE 4. Global Icosapent Ethyl Drugs Market, Data Triangulation
FIGURE 5. Global Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Icosapent Ethyl Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Icosapent Ethyl Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 9. Global Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Icosapent Ethyl Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Icosapent Ethyl Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Icosapent Ethyl Drugs Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Icosapent Ethyl Drugs Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Icosapent Ethyl Drugs Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 17. Global Icosapent Ethyl Drugs Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Icosapent Ethyl Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Icosapent Ethyl Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Icosapent Ethyl Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Icosapent Ethyl Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Icosapent Ethyl Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Icosapent Ethyl Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Icosapent Ethyl Drugs Market Segmentation & Coverage
TABLE 2. Global Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Pure Icosapent Ethyl Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Pure Icosapent Ethyl Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Pure Icosapent Ethyl Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Ethyl Ester Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Ethyl Ester Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Ethyl Ester Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Ethyl Ester Softgels Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Ethyl Ester Softgels Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Ethyl Ester Softgels Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Combination Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Combination Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Combination Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Icosapent Ethyl With Statins Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Icosapent Ethyl With Statins Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Icosapent Ethyl With Statins Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Icosapent Ethyl With Other Lipid Modifiers Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Icosapent Ethyl With Other Lipid Modifiers Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Icosapent Ethyl With Other Lipid Modifiers Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Research And Compounding Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Research And Compounding Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Research And Compounding Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Clinical Trial Supplies Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Clinical Trial Supplies Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Clinical Trial Supplies Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Compounded Preparations Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Compounded Preparations Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Compounded Preparations Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 32. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 39. Global Cardiovascular Risk Reduction Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Cardiovascular Risk Reduction Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Cardiovascular Risk Reduction Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Atherosclerotic Cardiovascular Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Atherosclerotic Cardiovascular Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Atherosclerotic Cardiovascular Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Diabetes With Cardiovascular Risk Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Diabetes With Cardiovascular Risk Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Diabetes With Cardiovascular Risk Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Hypertriglyceridemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hypertriglyceridemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hypertriglyceridemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Severe Hypertriglyceridemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Severe Hypertriglyceridemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Severe Hypertriglyceridemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Mild To Moderate Hypertriglyceridemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Mild To Moderate Hypertriglyceridemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Mild To Moderate Hypertriglyceridemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 58. Global Cardiovascular Risk Reduction Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Cardiovascular Risk Reduction Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Cardiovascular Risk Reduction Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Hypertriglyceridemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Hypertriglyceridemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Hypertriglyceridemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 65. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 75. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 97. North America Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. North America Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 99. North America Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 100. North America Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 101. North America Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 102. North America Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 103. North America Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. North America Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 105. North America Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 106. North America Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 107. North America Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. North America Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 109. Latin America Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Latin America Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 111. Latin America Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 112. Latin America Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 113. Latin America Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 114. Latin America Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 115. Latin America Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. Latin America Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 117. Latin America Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 118. Latin America Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 119. Latin America Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. Latin America Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 121. Europe Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Europe Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. Europe Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 124. Europe Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 125. Europe Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 126. Europe Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 127. Europe Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. Europe Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 129. Europe Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 130. Europe Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 131. Europe Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Europe Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 133. Middle East Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Middle East Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 135. Middle East Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 136. Middle East Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 137. Middle East Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 138. Middle East Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 139. Middle East Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. Middle East Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 141. Middle East Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 142. Middle East Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 143. Middle East Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. Middle East Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 145. Africa Icosapent Ethyl Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Africa Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. Africa Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 148. Africa Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 149. Africa Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 150. Africa Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 151. Africa Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. Africa Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 153. Africa Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 154. Africa Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 155. Africa Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. Africa Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 157. Global Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. ASEAN Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. ASEAN Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 160. ASEAN Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 161. ASEAN Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 162. ASEAN Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 163. ASEAN Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 164. ASEAN Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. ASEAN Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 166. ASEAN Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 167. ASEAN Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. ASEAN Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. ASEAN Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 170. GCC Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. GCC Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. GCC Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 173. GCC Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 174. GCC Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 175. GCC Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 176. GCC Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. GCC Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 178. GCC Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 179. GCC Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 180. GCC Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. GCC Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 182. European Union Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. European Union Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 184. European Union Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 185. European Union Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 186. European Union Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 187. European Union Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 188. European Union Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. European Union Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 190. European Union Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 191. European Union Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 192. European Union Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. European Union Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 194. BRICS Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. BRICS Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 196. BRICS Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 197. BRICS Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 198. BRICS Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 199. BRICS Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 200. BRICS Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. BRICS Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 202. BRICS Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 203. BRICS Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 204. BRICS Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. BRICS Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 206. G7 Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. G7 Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. G7 Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 209. G7 Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 210. G7 Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 211. G7 Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 212. G7 Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. G7 Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 214. G7 Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 215. G7 Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 216. G7 Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. G7 Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 218. NATO Icosapent Ethyl Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. NATO Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 220. NATO Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 221. NATO Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 222. NATO Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 223. NATO Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 224. NATO Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. NATO Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 226. NATO Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 227. NATO Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 228. NATO Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. NATO Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 230. Global Icosapent Ethyl Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 231. United States Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 232. United States Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 233. United States Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 234. United States Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 235. United States Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 236. United States Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 237. United States Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 238. United States Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 239. United States Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 240. United States Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 241. United States Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. United States Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 243. Canada Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 244. Canada Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 245. Canada Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 246. Canada Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 247. Canada Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 248. Canada Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 249. Canada Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. Canada Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 251. Canada Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 252. Canada Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 253. Canada Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. Canada Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 255. Mexico Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 256. Mexico Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 257. Mexico Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 258. Mexico Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 259. Mexico Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 260. Mexico Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 261. Mexico Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 262. Mexico Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 263. Mexico Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 264. Mexico Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 265. Mexico Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Mexico Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 267. Brazil Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 268. Brazil Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 269. Brazil Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 270. Brazil Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 271. Brazil Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 272. Brazil Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 273. Brazil Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 274. Brazil Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 275. Brazil Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 276. Brazil Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 277. Brazil Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 278. Brazil Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 279. United Kingdom Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 280. United Kingdom Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 281. United Kingdom Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 282. United Kingdom Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 283. United Kingdom Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 284. United Kingdom Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 285. United Kingdom Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 286. United Kingdom Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 287. United Kingdom Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 288. United Kingdom Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 289. United Kingdom Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 290. United Kingdom Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 291. Germany Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 292. Germany Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 293. Germany Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 294. Germany Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 295. Germany Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 296. Germany Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 297. Germany Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 298. Germany Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 299. Germany Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 300. Germany Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 301. Germany Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Germany Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 303. France Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 304. France Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 305. France Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 306. France Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 307. France Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 308. France Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 309. France Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 310. France Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 311. France Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 312. France Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 313. France Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 314. France Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 315. Russia Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 316. Russia Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 317. Russia Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 318. Russia Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 319. Russia Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 320. Russia Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 321. Russia Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 322. Russia Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 323. Russia Icosapent Ethyl Drugs Market Size, by Hypertriglyceridemia, 2017-2032 (USD Million)
TABLE 324. Russia Icosapent Ethyl Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 325. Russia Icosapent Ethyl Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 326. Russia Icosapent Ethyl Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 327. Italy Icosapent Ethyl Drugs Market Size, 2017-2032 (USD Million)
TABLE 328. Italy Icosapent Ethyl Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 329. Italy Icosapent Ethyl Drugs Market Size, by Pure Icosapent Ethyl Products, 2017-2032 (USD Million)
TABLE 330. Italy Icosapent Ethyl Drugs Market Size, by Combination Products, 2017-2032 (USD Million)
TABLE 331. Italy Icosapent Ethyl Drugs Market Size, by Research And Compounding Products, 2017-2032 (USD Million)
TABLE 332. Italy Icosapent Ethyl Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 333. Italy Icosapent Ethyl Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 334. Italy Icosapent Ethyl Drugs Market Size, by Cardiovascular Risk Reduction, 2017-2032 (USD Million)
TABLE 335. Italy Icosapent Ethyl Drugs Mar

Companies Mentioned

  • Alembic Pharmaceuticals Ltd.
  • Amarin Corporation plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Himalaya Global Holdings Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.

Related Topics

Related Reports

Omega-3 Prescription Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Product Type (EPA-only (Icosapent Ethyl), EPA + DHA Ethyl Esters, Omega-3 Carboxylic Acids, Pipeline High-Concentrate Formulations), Indication, Dosage Form, Distribution Channel - Product Image

Omega-3 Prescription Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Product Type (EPA-only (Icosapent Ethyl), EPA + DHA Ethyl Esters, Omega-3 Carboxylic Acids, Pipeline High-Concentrate Formulations), Indication, Dosage Form, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Lipid Regulators Market Report 2026 - Product Image

Lipid Regulators Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Atherosclerotic Cardiovascular Disease - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Atherosclerotic Cardiovascular Disease - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 356 Pages
  • Global
From
Candesartan Ethyl Ester (CAS 139481-58-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Candesartan Ethyl Ester (CAS 139481-58-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Cardiovascular Drugs Market - Global Forecast 2026-2032 - Product Image

Cardiovascular Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.